Breaking News
Get 40% Off 0
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did. Read how
Close

Vir Biotechnology Inc (VIR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Vir Biotech's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
9.44 -0.12    -1.26%
16:00:59 - Closed. Currency in USD ( Disclaimer )
After Hours
9.48
+0.04
+0.42%
18:39:29 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 577,361
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 9.36 - 9.72
Vir Biotech 9.44 -0.12 -1.26%

Vir Biotechnology Inc Company Profile

 
Get an in-depth profile of Vir Biotechnology Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

576

Equity Type

ORD

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Contact Information

Address 1800 Owens Street Suite 900
San Francisco, 94158
United States
Phone 415 906 4324
Fax -

Top Executives

Name Age Since Title
Francis V. Chisari - - Scientific Advisor
Vicki L. Sato 75 2016 Independent Chairman
Phillip A. Sharp 79 2017 Independent Director
George A. Scangos 76 2017 Director
Thomas O. Daniel 70 2017 Scientific Advisor
Jeffrey V. Ravetch 73 - Scientific Advisor
Robert J. Perez 60 2017 Independent Director
Robert J. More 56 2016 Independent Director
Jeffrey A. Bluestone 70 - Scientific Advisor
George H. Poste 80 - Scientific Advisor
Sona Saira Ramasastry 48 2019 Independent Director
Jeffrey S. Hatfield 66 2020 Independent Director
Emilio A. Emini 71 2015 Scientific Advisor
Robert Taylor Nelsen 62 2016 Independent Director
Charles Elliott Sigal 72 2020 Independent Director
Janet Napolitano 66 2020 Independent Director
Charles M. Rice - - Scientific Advisor
Susanna Naggie - - Scientific Advisor
Marianne De Backer 55 2023 CEO & Director
Lawrence Corey 76 2016 Co-Founder & Scientific Advisor
Louis J. Picker - - Co-Founder & Scientific Advisor
Klaus Frueh 64 2016 Co-Founder & Scientific Advisor
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

VIR Comments

Write your thoughts about Vir Biotechnology Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Constantin Nederita
Constantin Nederita Feb 19, 2024 8:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this company will be BIG soon $!
Alessandro Rossi
Alessandro Rossi Sep 10, 2023 7:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
anyone here?
Thomas Marcotte
Thomas Marcotte Mar 06, 2023 1:33PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Does anyone here think the 1H’23 readouts are going to keep this stock above its current value in the next 6 months?
Tom Papa
Tom Papa Mar 30, 2022 6:19AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Needham Maintains Buy on Vir Biotechnology, Lowers Price Target to $45
MIKHAIL KUZNETSOV
MIKHAIL KUZNETSOV Jan 30, 2022 8:59PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
While waiting for the catalyst, $35 was added. Flying to the moon is a matter of time 🚀🤑
Despoina Alterlife
Despoina Alterlife Jan 30, 2022 8:59PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Dear Brother from Bulgaria, when will rise the price do you have any opinion please ?
Akop Enokian
Akop Enokian Jan 23, 2022 11:21PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
On Monday Bull ran?
Tomás Turbado
Tomás Turbado Dec 07, 2021 7:02AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hi there,I have been having a look on this company and its numbers seem quite good isn´t?Here in Europe turned up the new about GSK and sotrovimab,apparently this treatment works(apparently....)and seeing the crash that happened yesterday with Vir and the pre market looks a good day to get in.If anyone had any other info I would really appreciate if shared it.Regards
Alexander Vasilyev
Alexander Vasilyev Dec 06, 2021 8:31AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It's the worst stock I ever hold... I only hope it will shoot on new data on Omicron
Edward LIM
Edward LIM Dec 01, 2021 6:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Do anyone know why VIR surged more than 40% over the past 3 days? New therapeutic product or treatment developed in regards to Omicron variant?
Lucky Spartanec
Lucky Spartanec Nov 23, 2021 10:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Some times later, you will see price of 200. When? There is no information,but its important to buy on time.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email